3.59
0.07 (1.96%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | ProMIS Neurosciences Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | 2.0 |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -1.7 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.05 |
Select this tab to load the latest available analysis.
|
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 27.56% |
| % Held by Institutions | 28.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Deep Track Capital, Lp | 30 Jun 2026 | 835,655 |
| Ally Bridge Group (Ny) Llc | 30 Jun 2026 | 620,319 |
| Trails Edge Capital Partners, Lp | 30 Jun 2026 | 557,103 |
| Squadron Capital Management Llc | 30 Jun 2026 | 324,977 |
| 683 Capital Management, Llc | 30 Jun 2026 | 95,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CASHMAN NEIL | 3.00 | - | 10,000 | 30,000 |
| WILLIAMS EUGENE | 3.31 | - | 1,316 | 4,356 |
| Aggregate Net Quantity | 11,316 | |||
| Aggregate Net Value ($) | 34,356 | |||
| Aggregate Avg. Buy ($) | 3.04 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CASHMAN NEIL | Officer | 02 Nov 2026 | Buy (+) | 10,000 | 3.00 | 30,000 |
| WILLIAMS EUGENE | Director | 30 Oct 2026 | Buy (+) | 1,316 | 3.31 | 4,356 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |